Joseph M Blondeau

List of Publications by Year
in descending order

66 papers	2,356 citations	361045 20 h-index	205818 48 g-index
68 all docs	68 docs citations	68 times ranked	2078 citing authors

#	Article	IF	Citations
1	Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2001, 45, 433-438.	1.4	299
2	Fluoroquinolones: mechanism of action, classification, and development of resistance. Survey of Ophthalmology, 2004, 49, S73-S78.	1.7	261
3	Antimicrobial Use Guidelines for Treatment of Urinary Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases. Veterinary Medicine International, 2011, 2011, 1-9.	0.6	252
4	International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats. Veterinary Journal, 2019, 247, 8-25.	0.6	231
5	Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (<scp>A</scp>ntimicrobial <scp>G</scp>uidelines <scp>W</scp>orking <scp>G</scp>roup of the) Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	219
6	A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new â€˜respiratory quinolonesâ€™. Journal of Antimicrobial Chemotherapy, 1999, 43, 1-11.	1.3	169
7	New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Veterinary Dermatology, 2009, 20, 383-396.	0.4	97
8	Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2006, 27, 120-124.	1.1	60
9	Mutant Prevention Concentration of Gemifloxacin for Clinical Isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2003, 47, 440-441.	1.4	48
10	MICs, MPCs and PK/PDs: a match (sometimes) made in hosts. Expert Review of Respiratory Medicine, 2007, 1, 7-16.	1.0	42
11	In vitro activity of tigecycline and comparators (2014â€“2016) among key WHO â€˜priority pathogensâ€™ and longitudinal assessment (2004â€“2016) of antimicrobial resistance: a report from the T.E.S.T. study. International Journal of Antimicrobial Agents, 2018, 52, 474-484.	1.1	41
12	Current Issues in the Management of Urinary Tract Infections. Drugs, 2004, 64, 611-628.	4.9	38
13	Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. Expert Opinion on Pharmacotherapy, 2001, 2, 317-335.	0.9	35
14	Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica. Veterinary Microbiology, 2012, 160, 85-90.	0.8	35
15	Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy, 2013, 68, 631-635.	1.3	35
16	The evolution and role of macrolides in infectious diseases. Expert Opinion on Pharmacotherapy, 2002, 3, 1131-1151.	0.9	33
17	In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Journal of Antimicrobial Chemotherapy, 1999, 43, 3-23.	1.3	26
18	Epidemiology of bacterial corneal ulcers at tertiary centres in Vancouver, B.C.. Canadian Journal of Ophthalmology, 2018, 53, 330-336.	0.4	26

#	Article	IF	Citations
19	Tetrasodium EDTA Is Effective at Eradicating Biofilms Formed by Clinically Relevant Microorganisms from Patientsâ€™ Central Venous Catheters. MSphere, 2018, 3, .	1.3	25
20	In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat. Veterinary Microbiology, 2012, 155, 284-290.	0.8	24
21	Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007â€“16 study. Journal of Antimicrobial Chemotherapy, 2019, 74, iv32-iv38.	1.3	23
22	Gatifloxacin: a new fluoroquinolone. Expert Opinion on Investigational Drugs, 2000, 9, 1877-1895.	1.9	20
23	A review of clinical trials with fluoroquinolones with an emphasis on new agents. Expert Opinion on Investigational Drugs, 2000, 9, 383-413.	1.9	19
24	Reporting elevated vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus: consensus by an International Working Group. Future Microbiology, 2019, 14, 345-352.	1.0	19
25	Gemifloxacin: a new fluoroquinolone. Expert Opinion on Pharmacotherapy, 2004, 5, 1117-1152.	0.9	18
26	Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis. PLoS ONE, 2019, 14, e0210154.	1.1	18
27	Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. Expert Opinion on Investigational Drugs, 2001, 10, 213-237.	1.9	16
28	Pradofloxacin: A novel veterinary fluoroquinolone for treatment of bacterial infections in cats. Veterinary Journal, 2014, 201, 207-214.	0.6	15
29	Besifloxacin in the management of bacterial infections of the ocular surface. Canadian Journal of Ophthalmology, 2015, 50, 184-191.	0.4	15
30	Quinupristin/dalfopristin. Expert Opinion on Pharmacotherapy, 2002, 3, 1341-1364.	0.9	14
31	The 24-h clinical microbiology service is essential for patient management. Future Microbiology, 2018, 13, 1625-1628.	1.0	14
32	Optimal antimicrobial therapy: the balance of potency and exposure. Expert Opinion on Investigational Drugs, 2006, 15, 335-337.	1.9	12
33	Application of Two Methods to Determine Killing ofStreptococcus pneumoniaeby Various Fluoroquinolones. Journal of Chemotherapy, 2006, 18, 366-372.	0.7	11
34	Comparative Minimal Inhibitory and Mutant Prevention Drug Concentrations of Four Fluoroquinolones Against Ocular Isolates of Haemophilus influenzae. Eye and Contact Lens, 2007, 33, 161-164.	0.8	11
35	Advances in laboratory diagnostic technologies in clinical microbiology and what this means for clinical practice. Clinical Practice (London, England), 2012, 9, 347-352.	0.1	11
36	Role of gemifloxacin in the management of community-acquired lower respiratory tract infections. International Journal of Antimicrobial Agents, 2008, 31, 299-306.	1.1	10

#	Article	IF	Citations
37	Urinary tract infection in a human male patient with Staphylococcus pseudintermedius transmission from the family dog. Journal of Chemotherapy, 2022, 34, 133-136.	0.7	10
38	Bactericidal effects of various concentrations of enrofloxacin, florfenicol, tilmicosin phosphate, and tulathromycin on clinical isolates of Mannheimia haemolytica. American Journal of Veterinary Research, 2015, 76, 860-868.	0.3	9
39	Persistent infection with Staphylococcus pseudintermedius in an adult oncology patient with transmission from a family dog. Journal of Chemotherapy, 2020, 32, 151-155.	0.7	9
40	Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%. PLoS ONE, 2020, 15, e0237603.	1.1	8
41	Bacteremia with Staphylococcus pseudintermedius in a 4 month old pediatric oncology patient. Journal of Chemotherapy, 2020, 32, 260-262.	0.7	8
42	Antibiotic dosing: do we dose to cure the individual or do we treat the greater societal needs?. Therapy: Open Access in Clinical Medicine, 2005, 2, 511-516.	0.2	7
43	Comparative in vitro killing of canine strains of Staphylococcus pseudintermedius and Escherichia coli by cefovecin, cefazolin, doxycycline and pradofloxacin. Veterinary Dermatology, 2016, 27, 267.	0.4	7
44	Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report. Future Microbiology, 2017, 12, 1523-1532.	1.0	7
45	Do we really understand what we want or need out of antimicrobial stewardship programs?. Clinical Practice (London, England), 2013, 10, 5-9.	0.1	5
46	Forensic, investigative and diagnostic microbiology: similar technologies but different priorities. Future Microbiology, 2019, 14, 553-558.	1.0	5
47	Clinical microbiology laboratories and COVID-19: the calm before the storm. Future Microbiology, 2020, 15, 1419-1424.	1.0	5
48	Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?. Expert Review of Anti-Infective Therapy, 2007, 5, 53-59.	2.0	4
49	In vitro killing of canine strains of Staphylococcus pseudintermedius and Escherichia coli by cefazolin, cefovecin, doxycycline and pradofloxacin over a range of bacterial densities. Veterinary Dermatology, 2020, 31, 187.	0.4	4
50	Antimicrobial resistance & â€˜Man's best friendâ€™: what they give to us we might be giving right back. Future Microbiology, 2017, 12, 549-553.	1.0	3
51	A pilot study on the comparative minimum inhibitory and mutant prevention concentration values for moxifloxacin and pradofloxacin against canine and human isolates of Staphylococcus pseudintermedius and S.Âschleiferi. Veterinary Dermatology, 2019, 30, 481.	0.4	3
52	Recovery of borderline oxacillin-resistant Staphylococcus pseudintermedius (BORSP) from bone and soft tissue of a rheumatoid arthritis patient with severe osteoporosis: transmission from the family dog. Journal of Chemotherapy, 2021, 33, 348-353.	0.7	3
53	Clinical microbiology laboratories and COVID-19: an interview with Joseph Blondeau. Future Microbiology, 2021, 16, 615-618.	1.0	3
54	In Vitro Killing of Canine Urinary Tract Infection Pathogens by Ampicillin, Cephalexin, Marbofloxacin, Pradofloxacin, and Trimethoprim/Sulfamethoxazole. Microorganisms, 2021, 9, 2279.	1.6	3

#	Article	IF	Citations
55	Bacteremia and polyarticular septic arthritis secondary to Moraxella bovis in a pregnant patient with HIV who injects drugs. Jammi, 0, , .	0.3	3
56	Macrocyclic antibiotics: a novel class of drug for the treatment ofClostridium difficileinfection. Expert Review of Clinical Pharmacology, 2012, 5, 9-11.	1.3	2
57	Quinolones and where they fit in todayâ€™s environment of multidrug-resistant bugs. Expert Review of Clinical Pharmacology, 2012, 5, 609-611.	1.3	1
58	Methicillin-resistant Staphylococcus aureus replication in the presence of high (â‰¥32 Âµg/ml) drug concentration of vancomycin as seen by electron microscopy. Journal of Chemotherapy, 2020, 32, 179-187.	0.7	1
59	Diagnostic clinical microbiology. Journal of Veterinary Pharmacology and Therapeutics, 2021, 44, 250-269.	0.6	1
60	In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride. Pharmaceuticals, 2021, 14, 517.	1.7	1
61	Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm. Therapy: Open Access in Clinical Medicine, 2005, 2, 357-373.	0.2	0
62	Antimicrobial development and the riskâ€“benefit assessment: recent adverse events and their implications. Expert Review of Anti-Infective Therapy, 2006, 4, 515-517.	2.0	0
63	Targeted drug delivery and drug resistant pathogens. Expert Review of Respiratory Medicine, 2018, 12, 161-164.	1.0	0
64	The inÂvitro antibacterial activity of the anthelmintic drug oxyclozanide against common small animal bacterial pathogens. Veterinary Dermatology, 2019, 30, 314.	0.4	0
65	Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm. Therapy: Open Access in Clinical Medicine, 2005, 2, 357-373.	0.2	0
66	Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%. Clinical Ophthalmology, 2021, Volume 15, 4419-4430.	0.9	0